Kary B. Mullis—Nobel Laureate for Procedure to Replicate DNA

Shampo, Marc A.; Kyle, Robert A.

doi:10.4065/77.7.606

Cited by 28 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…49 Polymerase Chain Reaction (PCR) was developed in the year 1983 by Kary Mullis for which he was awarded Nobel prize in chemistry in 1993. 50,51 The drawbacks of PCR is that Quantification is exceedingly difficult. 52 …”

Section: The Polymerase Chain Reaction (Pcr)mentioning

confidence: 99%

DNA Profiling and forensic dentistry – A review of the recent concepts and trends

Manjunath

Chandrashekar

Mahesh³

et al. 2011

Journal of Forensic and Legal Medicine

View full text Add to dashboard Cite

Section: The Polymerase Chain Reaction (Pcr)mentioning

confidence: 99%

DNA Profiling and forensic dentistry – A review of the recent concepts and trends

Manjunath

Chandrashekar

Mahesh³

et al. 2011

Journal of Forensic and Legal Medicine

View full text Add to dashboard Cite

“…It has been more than two decades since the introduction of PCR (Mullis et al, 1986, Shampo and Kyle, 2002). Although this technology was implemented almost immediately in research laboratories, it has only been within the past decade that new diagnostic PCR-based technologies are increasingly being integrated into clinical microbiology laboratory practice (Sobel et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Comparison of multiplex PCR hybridization-based and singleplex real-time PCR-based assays for detection of low prevalence pathogens in spiked samples

Hockman¹,

Dong

Zheng

et al. 2017

Journal of Microbiological Methods

View full text Add to dashboard Cite

Molecular diagnostic devices are increasingly finding utility in clinical laboratories. Demonstration of the effectiveness of these devices is dependent upon comparing results from clinical samples tested with the new device to an alternative testing method. The preparation of mock clinical specimens will be necessary for the validation of molecular diagnostic devices when a sufficient number of clinical specimens is unobtainable. Examples include rare pathogens, some of which are pathogens posing a biological weapon threat. Here we describe standardized steps for developers to follow for the culture and quantification of three organisms used to spike human whole blood to create mock specimens. The three organisms chosen for this study were the Live Vaccine Strain (LVS) of Francisella tularensis, surrogate for a potential biothreat pathogen, Escherichia coli, a representative Gram-negative bacterium and Babesia microti (Franca) Reichenow Peabody strain, representing a protozoan parasite. Mock specimens were prepared with blood from both healthy donors and donors with nonspecific symptoms including fever, malaise, and flu-like symptoms. There was no significant difference in detection results between the two groups for any pathogen. Testing of the mock samples was compared on two platforms, Target Enriched Multiplex-PCR (TEM-PCR™) and singleplex real-time PCR (RT-PCR). Results were reproducible on both platforms. The reproducibility demonstrated by obtaining the same results between two testing methods and between healthy and symptomatic mock specimens, indicates the standardized methods described for creating the mock specimens are valid and effective for evaluating diagnostic devices.

show abstract

“…It has been 12 decades since the inception of the PCR [1,2]. Although this technique was almost immediately implemented in research laboratories to study a variety of infectious diseases, among other processes, it has been within only the past 5-7 years that these assays have been made so user-friendly that they may be implemented in any microbiology laboratory [3].…”

mentioning

confidence: 99%

Molecular Diagnostics for the Detection and Characterization of Microbial Pathogens

Procop

2007

Clinical Infectious Diseases

101

View full text Add to dashboard Cite

New and advanced methods of molecular diagnostics are changing the way we practice clinical microbiology, which affects the practice of medicine. Signal amplification and real-time nucleic acid amplification technologies offer a sensitive and specific result with a more rapid turnaround time than has ever before been possible. Numerous methods of postamplification analysis afford the simultaneous detection and differentiation of numerous microbial pathogens, their mechanisms of resistance, and the construction of disease-specific assays. The technical feasibility of these assays has already been demonstrated. How these new, often more expensive tests will be incorporated into routine practice and the impact they will have on patient care remain to be determined. One of the most attractive uses for such techniques is to achieve a more rapid characterization of the infectious agent so that a narrower-spectrum antimicrobial agent may be used, which should have an impact on resistance patterns.

show abstract

Kary B. Mullis—Nobel Laureate for Procedure to Replicate DNA

Cited by 28 publications

References 0 publications

DNA Profiling and forensic dentistry – A review of the recent concepts and trends

DNA Profiling and forensic dentistry – A review of the recent concepts and trends

Comparison of multiplex PCR hybridization-based and singleplex real-time PCR-based assays for detection of low prevalence pathogens in spiked samples

Molecular Diagnostics for the Detection and Characterization of Microbial Pathogens

Contact Info

Product

Resources

About